A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)

NCT ID: NCT01003886

Last Updated: 2021-01-28

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

989 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-05-31

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to assess the safety, tolerability and efficacy of Doxazosin GITS in Filipino patients diagnosed with Benign Prostatic Hyperplasia (BPH) under the usual clinical care setting.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open label study. All patients prescribed with Doxazosin GITS can be enrolled in this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostatic Hyperplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open Label

Adult male diagnosed with BPH and prescribed with Doxazosin mesylate GITS

Doxazosin mesylate GITS

Intervention Type DRUG

Doxazosin mesylate GITS 4mg to 8mg once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Doxazosin mesylate GITS

Doxazosin mesylate GITS 4mg to 8mg once daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Alfadil XL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects that will be included must be consistent with the approved label indication of Doxazosin mesylate GITS in the Philippines, which includes adult male diagnosed with BPH, and who are prescribed with Doxazosin mesylate GITS.

Exclusion Criteria

* Subjects with condition that are contraindicated with Doxazosin mesylate GITS based on the approved labeling in the Philippines.
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Butuan, Agusan Del Norte, Philippines

Site Status

Pfizer Investigational Site

San Juan City, Batangas, Philippines

Site Status

Pfizer Investigational Site

Tagbilaran City, Bohol, Philippines

Site Status

Pfizer Investigational Site

Quezon City, Diliman, Philippines

Site Status

Pfizer Investigational Site

City of San Fernando, La Union, Philippines

Site Status

Pfizer Investigational Site

Ermita, Manila, Philippines

Site Status

Pfizer Investigational Site

Tondo, Manila, Philippines

Site Status

Pfizer Investigational Site

Diliman, Quezon City, National Capital Region, Philippines

Site Status

Pfizer Investigational Site

Pasig, National Capital Region, Philippines

Site Status

Pfizer Investigational Site

Angeles City, Pampanga, Philippines

Site Status

Pfizer Investigational Site

Angeles, , Philippines

Site Status

Pfizer Investigational Site

Angeles City, , Philippines

Site Status

Pfizer Investigational Site

Bacolod City, , Philippines

Site Status

Pfizer Investigational Site

Baguio City, , Philippines

Site Status

Pfizer Investigational Site

Bohol, , Philippines

Site Status

Pfizer Investigational Site

Bulacan, , Philippines

Site Status

Pfizer Investigational Site

Butuan, , Philippines

Site Status

Pfizer Investigational Site

Cagayan de Oro, , Philippines

Site Status

Pfizer Investigational Site

Cebu, , Philippines

Site Status

Pfizer Investigational Site

Cebu City, , Philippines

Site Status

Pfizer Investigational Site

Cebu City, , Philippines

Site Status

Pfizer Investigational Site

City of Muntinlupa, , Philippines

Site Status

Pfizer Investigational Site

Davao City, , Philippines

Site Status

Pfizer Investigational Site

Gallares City, , Philippines

Site Status

Pfizer Investigational Site

General Santos, , Philippines

Site Status

Pfizer Investigational Site

Iligan City, , Philippines

Site Status

Pfizer Investigational Site

Ilocos Norte, , Philippines

Site Status

Pfizer Investigational Site

Kalibo, , Philippines

Site Status

Pfizer Investigational Site

Kalibo Aklan, , Philippines

Site Status

Pfizer Investigational Site

La Union, , Philippines

Site Status

Pfizer Investigational Site

Laguna, , Philippines

Site Status

Pfizer Investigational Site

Laoag, , Philippines

Site Status

Pfizer Investigational Site

Lingayen, Pangasinan, , Philippines

Site Status

Pfizer Investigational Site

Makati City, , Philippines

Site Status

Pfizer Investigational Site

Malabon, , Philippines

Site Status

Pfizer Investigational Site

Manadaluyong, , Philippines

Site Status

Pfizer Investigational Site

Mandaluyong, , Philippines

Site Status

Pfizer Investigational Site

Mandaue City, , Philippines

Site Status

Pfizer Investigational Site

Manila, , Philippines

Site Status

Pfizer Investigational Site

Manila, , Philippines

Site Status

Pfizer Investigational Site

Marikina City, , Philippines

Site Status

Pfizer Investigational Site

Mindanaw, , Philippines

Site Status

Pfizer Investigational Site

Nueva Ecija, , Philippines

Site Status

Pfizer Investigational Site

Nueva Vizcaya, , Philippines

Site Status

Pfizer Investigational Site

Ozamiz, , Philippines

Site Status

Pfizer Investigational Site

Pampanga, , Philippines

Site Status

Pfizer Investigational Site

Pasig, , Philippines

Site Status

Pfizer Investigational Site

Philippines, , Philippines

Site Status

Pfizer Investigational Site

Quezon, , Philippines

Site Status

Pfizer Investigational Site

Quezon City, , Philippines

Site Status

Pfizer Investigational Site

Quezon City, , Philippines

Site Status

Pfizer Investigational Site

Quezon City, , Philippines

Site Status

Pfizer Investigational Site

Quezon City, , Philippines

Site Status

Pfizer Investigational Site

Rizal, , Philippines

Site Status

Pfizer Investigational Site

San Jose, , Philippines

Site Status

Pfizer Investigational Site

Surigao City, , Philippines

Site Status

Pfizer Investigational Site

Tacloban City, , Philippines

Site Status

Pfizer Investigational Site

Tagbilaran City, , Philippines

Site Status

Pfizer Investigational Site

Tagbilaran City, , Philippines

Site Status

Pfizer Investigational Site

Tagum, , Philippines

Site Status

Pfizer Investigational Site

Tarlac City, , Philippines

Site Status

Pfizer Investigational Site

Tarlac City, , Philippines

Site Status

Pfizer Investigational Site

Tuguegarao City, , Philippines

Site Status

Pfizer Investigational Site

Valenzuela, , Philippines

Site Status

Pfizer Investigational Site

Vigan, , Philippines

Site Status

Pfizer Investigational Site

Visayas, , Philippines

Site Status

Pfizer Investigational Site

West Fairview, Quezon City, , Philippines

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Philippines

Related Links

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A0351068

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

RT-310 Safety and Feasibility BPH Study
NCT07264205 RECRUITING PHASE1/PHASE2
A Study in Benign Prostatic Hyperplasia
NCT01152190 COMPLETED PHASE3